| Original language | English |
|---|---|
| Pages (from-to) | 92-98 |
| Number of pages | 7 |
| Journal | European Journal of Cancer |
| Volume | 91 |
| DOIs | |
| Publication status | Published - 1 Mar 2018 |
Keywords
- Non-small cell lung cancer
- Tyrosine kinase inhibitor
- QT interval
- Disease flare
- Drug monitoring
- CELL LUNG-CANCER
- 1ST-LINE TREATMENT
- PHASE-3 TRIAL
- OPEN-LABEL
- GEFITINIB
- ADENOCARCINOMA
- DACOMITINIB
- INHIBITOR
- ERLOTINIB
- INTERVAL
Cite this
}
Current perspective: Osimertinib-induced QT prolongation : new drugs with new side-effects need careful patient monitoring. / Schiefer, Mart; Hendriks, Lizza E. L.; Dinh, Dinh; Lalji, Ulrich; Dingemans, Anne-Marie C.
In: European Journal of Cancer, Vol. 91, 01.03.2018, p. 92-98.Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - Current perspective: Osimertinib-induced QT prolongation
T2 - new drugs with new side-effects need careful patient monitoring
AU - Schiefer, Mart
AU - Hendriks, Lizza E. L.
AU - Dinh, Dinh
AU - Lalji, Ulrich
AU - Dingemans, Anne-Marie C.
PY - 2018/3/1
Y1 - 2018/3/1
KW - Non-small cell lung cancer
KW - Tyrosine kinase inhibitor
KW - QT interval
KW - Disease flare
KW - Drug monitoring
KW - CELL LUNG-CANCER
KW - 1ST-LINE TREATMENT
KW - PHASE-3 TRIAL
KW - OPEN-LABEL
KW - GEFITINIB
KW - ADENOCARCINOMA
KW - DACOMITINIB
KW - INHIBITOR
KW - ERLOTINIB
KW - INTERVAL
U2 - 10.1016/j.ejca.2017.12.011
DO - 10.1016/j.ejca.2017.12.011
M3 - Article
VL - 91
SP - 92
EP - 98
JO - European Journal of Cancer
JF - European Journal of Cancer
SN - 0959-8049
ER -